Please assess the completion status of the following clinical trial:

Trial Title: Study of DU-176b Aged 80 Years or Older

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with Nonvalvular Atrial Fibrillation (NVAF) aged 80 years or older who are ineligible for available oral anticoagulation therapy~Exclusion Criteria:~* Patients with active bleeding~* Patients who have poorly controlled hypertension~* Patients who have liver dysfunction accompanied with disorder of blood coagulation

- Gender: ALL
- Minimum Age: 80 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- DU-176b 15 mg group (Type: EXPERIMENTAL): DU-176b orally administered at a dose of 15 mg once daily.
- Placebo group (Type: PLACEBO_COMPARATOR): Placebo orally administered once daily.

Based on this trial design, predict the completion outcome and termination type (if applicable).